NCT06166589View on ClinicalTrials.gov

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Previously AG Chemotherapy Treated Pancreatic Cancer
Interventions
DRUG

Zimberelimab

Zimberelimab, 240mg, day1. Every 3 weeks as a cycle.

DRUG

Oxaliplatin

Oxaliplatin 60mg/m2, day1、day8. Every 3 weeks as a cycle.

DRUG

S-1

S-1(BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; bid, day1-14). Every 3 weeks as a cycle.

DRUG

Irinotecan

Irinotecan, 130 mg/m2, day 1, day 8. Every 3 weeks as a cycle.

Trial Locations (1)

200000

Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06166589 - Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | Biotech Hunter | Biotech Hunter